JPMorgan Chase & Co. boosted its position in shares of UroGen Pharma Ltd. (NASDAQ:URGN - Free Report) by 263.1% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 68,062 shares of the company's stock after purchasing an additional 49,318 shares during the quarter. JPMorgan Chase & Co. owned about 0.29% of UroGen Pharma worth $864,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other institutional investors and hedge funds have also bought and sold shares of the company. Tidal Investments LLC grew its position in shares of UroGen Pharma by 19.1% during the 3rd quarter. Tidal Investments LLC now owns 37,595 shares of the company's stock worth $477,000 after buying an additional 6,030 shares in the last quarter. Barclays PLC grew its holdings in UroGen Pharma by 409.3% during the 3rd quarter. Barclays PLC now owns 59,778 shares of the company's stock worth $759,000 after acquiring an additional 48,040 shares in the last quarter. Geode Capital Management LLC increased its position in UroGen Pharma by 8.1% during the 3rd quarter. Geode Capital Management LLC now owns 455,637 shares of the company's stock valued at $5,787,000 after purchasing an additional 34,248 shares during the period. XTX Topco Ltd bought a new stake in shares of UroGen Pharma in the 3rd quarter valued at about $297,000. Finally, State Street Corp lifted its position in shares of UroGen Pharma by 5.9% in the 3rd quarter. State Street Corp now owns 769,583 shares of the company's stock worth $9,774,000 after purchasing an additional 42,907 shares during the period. 91.29% of the stock is owned by institutional investors.
Analyst Ratings Changes
Several equities analysts recently issued reports on the stock. HC Wainwright reissued a "buy" rating and set a $60.00 price objective on shares of UroGen Pharma in a report on Tuesday, October 15th. D. Boral Capital reissued a "buy" rating and issued a $25.00 price target on shares of UroGen Pharma in a research report on Thursday. Oppenheimer restated an "outperform" rating and set a $40.00 price objective on shares of UroGen Pharma in a research note on Wednesday, October 16th. Finally, EF Hutton Acquisition Co. I upgraded UroGen Pharma to a "strong-buy" rating in a research note on Monday, October 14th. Five research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus price target of $43.70.
Get Our Latest Report on UroGen Pharma
UroGen Pharma Stock Up 0.9 %
URGN stock traded up $0.09 on Friday, hitting $10.24. 143,649 shares of the company's stock were exchanged, compared to its average volume of 384,610. The company has a debt-to-equity ratio of 4.77, a quick ratio of 8.77 and a current ratio of 9.00. The stock has a market cap of $240.13 million, a P/E ratio of -3.25 and a beta of 1.09. The firm has a 50 day moving average price of $11.20 and a two-hundred day moving average price of $12.92. UroGen Pharma Ltd. has a 12-month low of $9.78 and a 12-month high of $20.70.
UroGen Pharma (NASDAQ:URGN - Get Free Report) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($0.55) EPS for the quarter, beating the consensus estimate of ($0.84) by $0.29. The company had revenue of $25.20 million during the quarter, compared to analysts' expectations of $24.22 million. During the same period in the previous year, the business earned ($0.68) earnings per share. As a group, equities research analysts expect that UroGen Pharma Ltd. will post -3.1 EPS for the current fiscal year.
UroGen Pharma Profile
(
Free Report)
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.
See Also
Before you consider UroGen Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and UroGen Pharma wasn't on the list.
While UroGen Pharma currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
